Cardiovascular risk: In HIV infected patients;Risco cardiovascular: Em doentes com infecção por vírus da imunodeficiência humana

Acta Medica Portuguesa

Volumn 23, Issue 4, 2010, Pages 669-676

  Raimundo, Pedro ^a   Miranda, A ^b   Ribeiro, J ^a   Mansinho, Kamal ^b  

^a HOSPITAL DE SÃO JOSÉ   (Portugal)

^b HOSPITAL EGAS MONIZ   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLIC DISORDER; REVIEW; VASCULAR ENDOTHELIUM; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; RISK FACTOR;

ANTILIPEMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 78349249088     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. HSUE P, WATERS D. What a Cardiologist needs to know about patients with HIV. Circulation 2005; 112:3947-57
2. STEIN J: Managing Cardiovascular Risk in Patients with HIV Infection. J Acquir Immune Defic Syndr 2005;38:115-123 (Pubitemid 40189317)
3. BERGERSEN BM: Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. Drugs 2006; 66(15):1971-87
4. MARY-KRAUSE M, COTTE L, SIMON A, PARTISANI M, COSTAGLIOLA D and the Clinical Epidemiology Group from the French Hospital Database: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-86
5. KANNEL WB, GIORDIANO M: Long-Term Cardiovascular Risk With Protease Inhibitors and Management of the Dyslipidemia. Am J Cardiol 2004;94:901-6
6. OH J, HEGELE R: HIV-associated dyslipidaemia:pathogenesis and treatment. Lancet Infect Dis 2007;7:787-796
7. MASIÁ-CANUTO M, BERNAL-MORELL E, GUTIÉRREZRODERO F: Alteraciones lipidicas y riesgo cardiovascular asociado a la terapia antiretroviral. Enferm Infecc Microbiol Clin 2006;24(10):637-648
8. DEPAIRON M, CHESSEX S, SUDRE P et al: Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals. Focus on protease inhibitor therapy. AIDS. 2001;15:329-34.
9. CURRIER JS, KENDALL MA, HENRY WK et al: Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 2007;21:1137-45
10. DE LARRANAGA GF, PETRONI A, DELUCHI G, ALONSO BC, BENETUCCI JÁ: Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus1 - infected patients. Blood Coagul Fibrinolysis 2003; 14(1):15-8
11. MARTIN S, TESSE A, HUGEL B et al: Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation 2004;109:1653-59
12. MANGILI A, JACOBSON DL, GERIIOR J, POLAK JF, GORBACH SL, WANKE CA: Metabolic Syndrome and subclinical atherosclerosis in patients infected with HIV. CID 2007;44:1368-74
13. RIDDLER SA, SMIT E, COLE SR et al: Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-82
14. CROOK M: The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment. Ann Clin Biochem 2007; 44(Pt3):219-231
15. ABOUD M, ELGALIB A, KULASEGARAM R, PETERS B: Insulin resistance and HIV infection: a review. Int J Clin Oract 2007; 61(3):463-472 (Pubitemid 46277019)
16. FRIIS-MOLLER N, WEBER R, REISS P et al: Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy: results from the DAD study. AIDS. 2003;17:1179-93
17. SQUIRES K, LAZZARIN A, GATELL JM et al: Comparison of once-daily atazanavir with efavirenz, each in combination with fixed dose zidovudine and Lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011-9
18. BARBARO P: HIV infection, antiretroviral therapy and cardiovascular risk. Journal of Cardiovascular Risk 2002;9:295-300 (Pubitemid 35283732)
19. WOHL DA, MC-COMSEY G, TEBAS P et al: Current Concepts in the Diagnosis and Management of Metabolic Complications of HIV Infection and Its Therapy. CID 2006;43:645-653
20. DUBÉ MP, STEIN JH, ABERG JA et al: Guidelines for the Evaluation and Mangement of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. CID 2003;37:613-627 (http://www.nhlbi.nih. gov/guidelines/cholesterol/index.htm)
21. FLIERS E, SAUERWEIN HP, ROMIJN JA et al: HIV - associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet 2003;362:1758-60
22. MARTINEZ E, MOCROFT A, GARCIA-VIEJO MA et al: Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors; a prospective cohort study. Lancet 2001;357:592-8
23. JERICÓ C, KNOBEL H, MONTERO M et al: Metabolic Syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005;1:132-7
24. SAMARAS K, WAND H, LAW M et al: prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria. Diabetes Care 2007; 30:113-9
25. Executive Summary. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97
26. GERBER JG, ROSENKRANZ SL, FICHTENBAUM CJ et al: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study. J Acquir Immune Defic Syndr 2005;39:307-12.
27. CALZA L, MANFREDI R, COLANGELI V et al: Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidemia. AIDS 2005;19:1051-8
28. DOMINGO P, LABARGA P, PALACIOS R et al: RECOVER Study Group. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004; 18:1475-8